C-type lectin domain family 4 member MGenealiases: CD209L · CD209L1 · CD299 · DC-SIGN2 · DC-SIGNR · DCSIGNR
Q-omics provides the consensus-scored CLEC4M profile across patient tissues and cancer cell-line models. CLEC4M expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, CLEC4M is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, CLEC4M RNA expression shows 6,984 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, KIRC, and STAD as cancer lineages where CLEC4M shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLEC4M — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLEC4M survival associations across molecular data types. CLEC4M RNA expression shows survival associations in the most cancer types (18), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLEC4M RNA expression–survival associations across cancer types. High CLEC4M expression shows unfavorable associations in LUSC, THCA, KIRC, KICH and STAD, but favorable associations in ESCA. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for CLEC4M RNA expression.
This table summarizes CLEC4M tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CLEC4M. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLEC4M shows lower tumor expression in KIRC, COAD, LIHC, LUSC and LUAD and higher tumor expression in HNSC. The KIRC box plot shows higher CLEC4M RNA expression in normal versus tumor tissue (log2 FC = −0.119, t-test p < 0.001).
This table shows molecular features associated with CLEC4M in patient tissues and cancer cell lines. In patient samples, CLEC4M shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CLEC4M RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
